Angiotensin II type 1 receptor antagonist attenuates lung fibrosis in hyperoxia-exposed newborn rats

Hsiu Chu Chou, Yaw Dong Lang, Leng-Fang Wang, Tzu Ying Wu, Yu Fang Hsieh, Chung Ming Chen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Bronchopulmonary dysplasia (BPD) remains a major cause of morbidity and mortality during the first year of life, and many infants have significant respiratory problems throughout childhood. Currently no effective therapy is clinically available to prevent the long-term pulmonary sequelae of BPD. Previous research has demonstrated that the renin-angiotensin system is up-regulated in human lung fibroblasts. Angiotensin II type 1 receptor (AT 1R) antagonists and AT 1R short interfering RNA diminished hyperoxia-increased collagen expression, whereas AT 2R antagonists did not have any effects on these hyperoxia-induced changes. The in vivo therapeutic effects of AT 1R antagonists on hyperoxia-induced lung fibrosis remain unknown. The present study assessed the effects of an AT 1R antagonist (losartan) on preventing hyperoxia-induced lung fibrosis in newborn rats. Rat pups were exposed to 7 days of >95% O 2 and an additional 2 weeks of 60% O 2. AT 1R antagonist-treated pups were injected intraperitoneally with losartan at a dose of 10 mg/kg/day from postnatal days 1 to 7 and a dose of 5 mg/kg/day from postnatal days 8 to 21. Control group pups were injected with an equal volume of normal saline. AT 1R antagonist treatment attenuated the hyperoxia-induced lung fibrosis on postnatal days 7 and 21 and also decreased the hyperoxia-induced expression of extracellular signal-regulated protein kinase and α-smooth muscle actin. AT 1R antagonist treatment did not affect body weight or lung weight of the rats. These data suggest that AT 1R antagonist may offer a novel therapeutic strategy for preventing hyperoxia-induced lung fibrosis.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume340
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Hyperoxia
Fibrosis
Lung
Bronchopulmonary Dysplasia
Losartan
Angiotensin Type 1 Receptor
Extracellular Signal-Regulated MAP Kinases
Therapeutic Uses
Therapeutics
Renin-Angiotensin System
Protein Kinases
Small Interfering RNA
Smooth Muscle
Actins
Collagen
Fibroblasts
Body Weight
Morbidity
Weights and Measures

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Angiotensin II type 1 receptor antagonist attenuates lung fibrosis in hyperoxia-exposed newborn rats. / Chou, Hsiu Chu; Lang, Yaw Dong; Wang, Leng-Fang; Wu, Tzu Ying; Hsieh, Yu Fang; Chen, Chung Ming.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 340, No. 1, 01.2012, p. 169-175.

Research output: Contribution to journalArticle

@article{a9ecc33ba9a74fa9b89885389229d107,
title = "Angiotensin II type 1 receptor antagonist attenuates lung fibrosis in hyperoxia-exposed newborn rats",
abstract = "Bronchopulmonary dysplasia (BPD) remains a major cause of morbidity and mortality during the first year of life, and many infants have significant respiratory problems throughout childhood. Currently no effective therapy is clinically available to prevent the long-term pulmonary sequelae of BPD. Previous research has demonstrated that the renin-angiotensin system is up-regulated in human lung fibroblasts. Angiotensin II type 1 receptor (AT 1R) antagonists and AT 1R short interfering RNA diminished hyperoxia-increased collagen expression, whereas AT 2R antagonists did not have any effects on these hyperoxia-induced changes. The in vivo therapeutic effects of AT 1R antagonists on hyperoxia-induced lung fibrosis remain unknown. The present study assessed the effects of an AT 1R antagonist (losartan) on preventing hyperoxia-induced lung fibrosis in newborn rats. Rat pups were exposed to 7 days of >95{\%} O 2 and an additional 2 weeks of 60{\%} O 2. AT 1R antagonist-treated pups were injected intraperitoneally with losartan at a dose of 10 mg/kg/day from postnatal days 1 to 7 and a dose of 5 mg/kg/day from postnatal days 8 to 21. Control group pups were injected with an equal volume of normal saline. AT 1R antagonist treatment attenuated the hyperoxia-induced lung fibrosis on postnatal days 7 and 21 and also decreased the hyperoxia-induced expression of extracellular signal-regulated protein kinase and α-smooth muscle actin. AT 1R antagonist treatment did not affect body weight or lung weight of the rats. These data suggest that AT 1R antagonist may offer a novel therapeutic strategy for preventing hyperoxia-induced lung fibrosis.",
author = "Chou, {Hsiu Chu} and Lang, {Yaw Dong} and Leng-Fang Wang and Wu, {Tzu Ying} and Hsieh, {Yu Fang} and Chen, {Chung Ming}",
year = "2012",
month = "1",
doi = "10.1124/jpet.111.186288",
language = "English",
volume = "340",
pages = "169--175",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Angiotensin II type 1 receptor antagonist attenuates lung fibrosis in hyperoxia-exposed newborn rats

AU - Chou, Hsiu Chu

AU - Lang, Yaw Dong

AU - Wang, Leng-Fang

AU - Wu, Tzu Ying

AU - Hsieh, Yu Fang

AU - Chen, Chung Ming

PY - 2012/1

Y1 - 2012/1

N2 - Bronchopulmonary dysplasia (BPD) remains a major cause of morbidity and mortality during the first year of life, and many infants have significant respiratory problems throughout childhood. Currently no effective therapy is clinically available to prevent the long-term pulmonary sequelae of BPD. Previous research has demonstrated that the renin-angiotensin system is up-regulated in human lung fibroblasts. Angiotensin II type 1 receptor (AT 1R) antagonists and AT 1R short interfering RNA diminished hyperoxia-increased collagen expression, whereas AT 2R antagonists did not have any effects on these hyperoxia-induced changes. The in vivo therapeutic effects of AT 1R antagonists on hyperoxia-induced lung fibrosis remain unknown. The present study assessed the effects of an AT 1R antagonist (losartan) on preventing hyperoxia-induced lung fibrosis in newborn rats. Rat pups were exposed to 7 days of >95% O 2 and an additional 2 weeks of 60% O 2. AT 1R antagonist-treated pups were injected intraperitoneally with losartan at a dose of 10 mg/kg/day from postnatal days 1 to 7 and a dose of 5 mg/kg/day from postnatal days 8 to 21. Control group pups were injected with an equal volume of normal saline. AT 1R antagonist treatment attenuated the hyperoxia-induced lung fibrosis on postnatal days 7 and 21 and also decreased the hyperoxia-induced expression of extracellular signal-regulated protein kinase and α-smooth muscle actin. AT 1R antagonist treatment did not affect body weight or lung weight of the rats. These data suggest that AT 1R antagonist may offer a novel therapeutic strategy for preventing hyperoxia-induced lung fibrosis.

AB - Bronchopulmonary dysplasia (BPD) remains a major cause of morbidity and mortality during the first year of life, and many infants have significant respiratory problems throughout childhood. Currently no effective therapy is clinically available to prevent the long-term pulmonary sequelae of BPD. Previous research has demonstrated that the renin-angiotensin system is up-regulated in human lung fibroblasts. Angiotensin II type 1 receptor (AT 1R) antagonists and AT 1R short interfering RNA diminished hyperoxia-increased collagen expression, whereas AT 2R antagonists did not have any effects on these hyperoxia-induced changes. The in vivo therapeutic effects of AT 1R antagonists on hyperoxia-induced lung fibrosis remain unknown. The present study assessed the effects of an AT 1R antagonist (losartan) on preventing hyperoxia-induced lung fibrosis in newborn rats. Rat pups were exposed to 7 days of >95% O 2 and an additional 2 weeks of 60% O 2. AT 1R antagonist-treated pups were injected intraperitoneally with losartan at a dose of 10 mg/kg/day from postnatal days 1 to 7 and a dose of 5 mg/kg/day from postnatal days 8 to 21. Control group pups were injected with an equal volume of normal saline. AT 1R antagonist treatment attenuated the hyperoxia-induced lung fibrosis on postnatal days 7 and 21 and also decreased the hyperoxia-induced expression of extracellular signal-regulated protein kinase and α-smooth muscle actin. AT 1R antagonist treatment did not affect body weight or lung weight of the rats. These data suggest that AT 1R antagonist may offer a novel therapeutic strategy for preventing hyperoxia-induced lung fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=84055177945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055177945&partnerID=8YFLogxK

U2 - 10.1124/jpet.111.186288

DO - 10.1124/jpet.111.186288

M3 - Article

C2 - 22005041

AN - SCOPUS:84055177945

VL - 340

SP - 169

EP - 175

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -